肿瘤药学2025，Vol.15Issue(5)：565-571,7.DOI:10.3969/j.issn.2095-1264.2025.05.01
2025年ASCO乳腺癌重要研究进展
Key research advances in breast cancer at the 2025 ASCO annual meeting
摘要
Abstract
At the 2025 American Society of Clinical Oncology(ASCO)annual meeting,several pivotal studies in the field of breast cancer were presented,covering major molecular subtypes including HR+/HER2-,HER2-positive,and tri-ple-negative breast cancer(TNBC).These advances further promote precision and stratified treatment strategies.CDK4/6 inhibitors showed favorable results in the adjuvant setting,with the DAWNA-A and NATALEE trials confirming their effi-cacy in Chinese and premenopausal populations,respectively.Novel oral selective estrogen receptor degraders(SERDs),in-cluding imlunestrant,camizestrant,and vepdegestrant,demonstrated promising efficacy and safety in multiple phase Ⅲ tri-als.For patients with PIK3CA-mutated tumors,the PI3Kα inhibitor inavolisib significantly improved survival outcomes and delayed the need for chemotherapy.In the HER2-positive subtype,the DESTINY-Breast09 trial revealed that trastu-zumab deruxtecan(T-DXd)combined with pertuzumab outperformed the conventional chemotherapy plus dual HER2-tar-geted regimen as first-line treatment.Additionally,the Chinese-led neoCARHP trial provided evidence supporting the non-inferiority and lower toxicity of a carboplatin-sparing neoadjuvant approach.For TNBC,the ASCENT-04/KEYNOTE-D19 trial demonstrated that sacituzumab govitecan combined with pembrolizumab offered superior progression-free surviv-al compared to standard chemotherapy plus immunotherapy in PD-L1-positive patients.Moreover,studies on the prognostic impact of BRCA mutation types and ctDNA-guided dynamic treatment interventions attracted notable attention.This re-view summarizes the major breast cancer-related findings presented at the 2025 ASCO Annual Meeting and discusses their potential implications for clinical practice and future research.关键词
乳腺癌/ASCO/CDK4/6抑制剂/SERD/ADC/免疫治疗/ctDNAKey words
Breast cancer/ASCO/CDK4/6 inhibitors/SERD/ADC/Immunotherapy/ctDNA分类
医药卫生引用本文复制引用
LIU Binliang,HU Zheyu,XIE Ning,OUYANG Quchang..2025年ASCO乳腺癌重要研究进展[J].肿瘤药学,2025,15(5):565-571,7.基金项目
湖南省自然科学基金资助项目(2023JJ60464) （2023JJ60464）
湖南省自然科学基金青年基金资助项目(2024JJ6289) （2024JJ6289）
长沙市自然科学基金资助项目(kq2403120) （kq2403120）
湖南省肿瘤医院攀登计划资助项目(ZX2021005) （ZX2021005）
湖南省肿瘤医院攀登计划启航基金资助项目(QH2023006) （QH2023006）
湖南省肿瘤医院高层次人才五年行动计划支持(20250731-1050). （20250731-1050）
